Abstract | OBJECTIVE AND DESIGN: : To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care. PATIENTS AND METHODS: : Seventy-three percent of the patients had high-risk disease, defined by stage, performance status, extranodal sites and lactate dehydrogenase. The median CD4 cell count at diagnosis of HIV-BL was 171/ml (range: 4-848) and the plasma HIV viral load was undetectable in five of 29 patients. RESULTS: : Nine patients died during treatment ( disease progression, three; toxicity, five; central nervous system lesion not biopsied, one). Response rate was 70% (complete response/complete response uncertain, 17; partial response, 4). After a median follow-up of 22 months (range: 6-72), 18 patients remain alive without disease progression. The 3-year overall survival and event-free survival were 52 and 75%, respectively. Viral load was undetectable in 88% and CD4 cell count more than 200/ml in 58% of patients assessed 6 months after completing chemotherapy, and in 87 and 80% at 12 months, respectively. CONCLUSION: : The intensive regimen CODOX-M/IVAC, a feasible and effective chemotherapy, is associated with an excellent immunological recovery in patients with HIV-BL on HAART.
|
Authors | Silvia Montoto, Jamie Wilson, Kate Shaw, Maureen Heath, Andy Wilson, Christopher McNamara, Chloe Orkin, Mark Nelson, Margaret Johnson, Mark Bower, Kate Cwynarski |
Journal | AIDS (London, England)
(AIDS)
Vol. 24
Issue 6
Pg. 851-6
(Mar 27 2010)
ISSN: 1473-5571 [Electronic] England |
PMID | 20124971
(Publication Type: Journal Article)
|
Chemical References |
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Methotrexate
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Antiretroviral Therapy, Highly Active
- Burkitt Lymphoma
(drug therapy, immunology, mortality)
- CD4 Lymphocyte Count
- Cyclophosphamide
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Female
- HIV Infections
(drug therapy, immunology, mortality)
- Humans
- Lymphoma, AIDS-Related
(drug therapy, immunology, mortality)
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Prognosis
- Retrospective Studies
- Treatment Outcome
- Vincristine
(administration & dosage)
|